



CLEARPOINT®
NEURO

WHEN YOUR PATH IS UNCLEAR,
WE POINT THE WAY.

Nasdaq: CLPT

March 2024



This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company's expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results. These forward looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2023, both of which have been filed with the Securities and Exchange Commission, and the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2024. The Company does not assume any obligation to update these forward-looking statements.



CLEARPOINT[®]


NEURO

Our Company

We Are a Device, Cell and Gene Therapy-Enabling Company, Offering Precise Navigation to the Brain and Spine


We Uniquely Provide Both Established Clinical Products as well as Pre-Clinical Development Services for Controlled Drug and Device Delivery

A Precision Navigation Company Supporting...



50+ Biotech & Pharma Partners:

- Drug Navigation, Combination-Infusion Devices, A.I. Monitoring Solutions
- Established Quality System and Custom Device Development
- Translational Pre-Clinical, Clinical Trial & Regulatory Services



100+ Global Neurosurgeons:

- Expanding Navigation Systems for both the MRI & Operating Room
- An FDA Cleared Second-Generation Laser Therapy System
- 20+ Global Specialists Providing On-Site Training & Quality Control



Built On a Strong Foundation:

- 20,000 sq. ft. Manufacturing, R&D Lab
- Regulatory Approvals (FDA, CE, more)
- Established, Audited Quality System
- More than 100 Issued Patents*
- 10 Years of Revenue, 7,000+ Procedures

A \$12B+ TAM Diversified Across 35+ Indications and 50+ Partners

The ClearPoint® Neuro Navigation System


Leverage live MR Imaging to Decide, Guide, and Confirm with sub-millimetric accuracy



Pre-Plan Trajectory and
Decide Entry Point



Automatically *Guide*
Precision Adjustments Prior to
Insertion




Confirm Quality of Delivery
Into Permanent Record

Our Company


The ClearPoint® Neuro Navigation System: 10+ Years of Experience

Capital Hardware and Software


ClearPoint Neuro
Navigation
Software v.2.2



ClearPoint
Array® Software
v.1.2



ClearPoint
Maestro®
Brain Model



Inflexion® Head
Fixation Frame



Multi-Positional
Head Fixation
Frame




MRI Monitor

ClearPoint Prism®
Neuro Laser
Therapy System





Disposables


SmartFrame® XG with
Skull Mount Base




SmartFrame Array®
Kit Components



Accessory Kit (4Fr, 5Fr, and 7Fr Available)



SmartFlow Cannula



ClearPoint Prism®
Neuro Laser Fibers

A Strong Foundation

Key Products: **FDA** **CE** Marked Platforms

HEADQUARTERS

Solana Beach, CA

MANUFACTURING

Carlsbad, CA

2024 REVENUE GUIDANCE

\$28 m - \$32 m^(A)

CASH & CASH EQUIVALENTS

\$23.1 m^(B)

PATENTS ISSUED

100+^(C)

GROSS MARGIN

57%^(D)

EMPLOYEES


100+

QUALITY SYSTEM

MD-SAP

(A) Estimated and subject to revision
(B) For the quarter ended December 31, 2023
(C) Including owned and licensed patents
(D) For the Trailing Twelve Months (TTM)

10 Years of Continued Product Sales and Revenue Growth



A Strong Foundation

- 1,500 sq. ft Class 8 Clean Room with Expansion Capability
- 1,300 sq. ft Dedicated R&D Lab Space
- ISO 13485/MDSAP/EU MDR Certified Quality System
- Successful Audit Outcomes from Global Regulatory Bodies and Pharma
- Training Facility with over 100 Surgeons and Pharma Scientist Visitors



75+ Global Centers

Banner Health Tucson
Baptist Medical Center Jacksonville
Barnes-Jewish Hospital
Benioff Children's Hospital
Beth Israel Deaconess
Boston Children's Hospital
Brigham & Women's Hospital
Carilion Clinic
Children's Hospital of Alabama
Children's Hospital of Philadelphia
Children's Mercy Hospital
Children's National Hospital
CHOA Scottish Rite
Cincinnati Children's Hospital
Cincinnati Jewish Hospital
Cook Children's Hospital
Dallas Presbyterian Hospital
Dartmouth-Hitchcock
Duke University
Emory University
Froedtert Hospital
Hackensack University Medical Center
Henry Ford Health
Hospital of University Pennsylvania
Houston Methodist Hospital
INOVA Fairfax
JFK University Medical Center
Johns Hopkins University
Kaleida Health
Kettering Health
Loma Linda University Health
Lucile Packard Children's Hospital

Massachusetts General Hospital
Mayo Clinic in Arizona
Mayo Clinic in Florida
MD Anderson Cancer Center
MedStar Georgetown University Hospital
Memorial Sloan-Kettering Cancer Center
Methodist Hospital San Antonio
Mt. Sinai West
Nationwide Children's
Northwestern Central DuPage
Oschner Medical Center
Ohio State University
Riverside Methodist Hospital
San Francisco VA
Stanford University
Tampa General Hospital

Texas Children's Hospital
University of California San Diego
University of California San Francisco
University of Alabama at Birmingham
University of Colorado
University of Kansas Medical Center
University of Michigan
University of Minnesota
University of Oklahoma Medical Center
University of Utah
University of Virginia
University of Wisconsin
USC Keck Hospital
UT Southwestern Medical Center
Weill Cornell Medicine
Yale University

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (Milan, Italy)
Great Ormond Street Hospital (London, UK)
Hôpital Fondation Rothschild (Paris, France)
Hospital Israelita Albert Einstein (São Paulo, Brazil)
Hospital Santa Joana (Recife, Brazil)
Mazowiecki Szpital Bródnowski (Warsaw, Poland)
Policlinico Umberto I (Rome, Italy)
Rigshospitalet (Copenhagen, Denmark)
Sahlgrenska Universitetssjukhuset (Gothenburg, Sweden)
Skånes Universitetssjukhus Lund (Lund, Sweden)
TIDU GENOV - Institut du Cerveau (Paris, France)
Universitätsklinikum Düsseldorf (Düsseldorf, Germany)
Universitätsklinikum Freiburg (Freiburg, Germany)
University Hospital of Wales (Cardiff, UK)

Charles River Labs (Laval, Canada)
Charles River Labs (Lyon, France)
Charles River Labs (Mattawan, Canada)
Prisys Biotechnologies (Shanghai, China)

100+
Centers
Expected
by 2025

The ClearPoint Platform has been used in over 7,000 procedures

1 Biologics & Drug Delivery*



AskBio

Spark



BlueRock
Therapeutics



uniQure



AVIADO BIO



Aspen
NEUROSCIENCE

charles river

...with 50+ industry and academic partners

2 Navigation for DBS

Medtronic

Boston
Scientific



NEUROPACE



Abbott

3 Laser Therapy



CLEARPOINT

PRISM

MONTERIS[®]
MEDICAL

Medtronic

VISUALASE

ClearPoint Navigation is Compatible with all Major
Diagnostic and Intraoperative MRI Scanners

SIEMENS
Healthineers



































PHILIPS

IMRIS



~\$12B+ Opportunity: Empowering Multiple Treatment Options for 35+ Indications*

	Indication	Patient Population	Annual Incidence	Pillar 1: Drug/Cell Delivery	Pillar 2: DBS & BCI	Pillar 3: Laser Therapy	Incremental Revenue from Annual Incidence
ESTIMATED LAUNCH SEQUENCE	Parkinson's Disease	1,000,000 ¹	60,000 ¹	 			\$270 M - \$1.35 B
	Drug Resistant Epilepsy	1,000,000 ²	11,000 ³	 			\$49.5 M - \$198 M
	Refractory Essential Tremor	3,500,000 ⁴	60,000 ⁵				\$180 M - \$1.08 B
	Brain Tumors (n=3) ⁶	35,000 ^{7,8}	13,300 ^{7,8}	 			\$33.3 M - \$300 M
	Severe Obsessive-Compulsive Disorder	500,000 ^{9,10}	10,000 ^{9,10}				\$45 M - \$75 M
	Dystonia	250,000 ¹¹	8,000 ¹²				\$36 M - \$60 M
	Rare Genetic/Lysosomal (n=7) ¹³	36,500 ¹⁴⁻¹⁸	3,000 ^{14,19,20}	 			\$13.5 M - \$67.5 M
	Paralysis / Spinal Cord (n=15) ^{21,22}	331,000 ²²⁻²⁴	17,900 ²³	 			\$80.6 M - \$403 M
	Huntington's Disease	30,000 ²⁵	4,000 ²⁵	 			\$18 M - \$90 M
	Alzheimer's Disease	6,000,000 ²⁶	500,000 ²⁶	 			\$1.5 B - \$11.3 B
	Severe Major Depressive Disorder	1,000,000 ¹⁰	20,000 ^{10,27}				\$90 M - \$150 M
	Stroke Rehabilitation	2,000,000 ²⁸	610,000 ²⁸				\$1.83 B - \$5.49 B
	Frontotemporal Dementia	60,000 ²⁹	12,000 ²⁹				\$54 M - \$270 M
							\$4.2 B - \$20.8 B

-  Commercial U.S or EU ClearPoint procedures today
-  Active clinical trial
-  Pre-clinical study/testing

Citations & Footnotes

1. “Parkinson’s Disease Statistics,” Parkinson’s News Today, <https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older>
2. Neurona Therapeutics. (2021 November 4). *Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients* [Press release] https://www.neuronatherapeutics.com/wp-content/uploads/2021/11/2021_11_01_-INDClearance_FINALVersion.pdf
3. Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and Incidence of Drug-Resistant Mesial Temporal Lobe Epilepsy in the United States. *World Neurosurg.* 2017;99:662-666.
4. Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. *Neuropsychiatr Dis Treat.* 2010;6:401-408. Published 2010 Sep 7.
5. Diaz NL, Louis ED. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. *Parkinsonism Relat Disord.* 2010;16(9):604-607.
6. Includes: Glioblastoma, Diffuse Intrinsic Pontine Glioma and deep small eloquent brain tumors.
7. “Glioblastoma Multiforme,” American Association of Neurological Surgeons, <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme>
8. “About DIPG/DMG,” DIPG/DMG Registry, <https://dipgregistry.org/patients-families/about-dipg-dmg/>
9. Medtronic Clinical Summary – Reclaim DBS for Chronic Extreme OCD M947128A001.
10. Mantovani A, Lisanby SH. Brain stimulation in the treatment of anxiety disorders. In: Simpson HB, Neria Y, Lewis-Fernández R, Schneier F, eds. *Anxiety Disorders: Theory, Research and Clinical Perspectives*. Cambridge: Cambridge University Press; 2010:323-335.
11. <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Dystonia>
12. Medtronic DBS™ Therapy for Dystonia - Clinical Summary 2015.
13. Includes: AADC deficiency, Friedreich’s ataxia, Angelman syndrome, multiple system atrophy, metachromatic leukodystrophy, and spinocerebellar ataxia type 3.
14. “Multiple System Atrophy,” Medscape, <https://emedicine.medscape.com/article/1154583-overview#a6>
15. PTC Therapeutics November 30, 2021 Corporate Presentation, <https://ir.ptcbio.com/static-files/0fd5d54f-55b8-416b-8006-4eb4c0d82f45>
16. “Spinocerebellar ataxia type 3,” Orphanet, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=98757
17. Lysogene Corporate Presentation at 38th Annual J.P. Morgan Healthcare Conference on Jan 13, 2020, http://www.lysogene.com/wp-content/uploads/2020/01/jpm-2020-corporate-presentation_final.pdf
18. “Metachromatic Leukodystrophy,” National Organization of Rare Disorders, <https://rarediseases.org/rare-diseases/metachromatic-leukodystrophy/>
19. “Aromatic L’Amino Acid Decarboxylase Deficiency,” National Organization for Rare Disorders, <https://rarediseases.org/rare-diseases/aromatic-l-amino-acid-decarboxylase-deficiency/>
20. Puckett Y, Mallorga-Hernández A, Montaña AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. *Orphanet J Rare Dis.* 2021;16(1):241. Published 2021 May 29.
21. Includes: stroke, spinal cord injury, multiple sclerosis, cerebral palsy, other (traumatic brain injury, complications from surgery, amyotrophic lateral sclerosis, neurofibromatosis, Chiari malformation, syringomyelia, postpolio syndrome, spinal muscular atrophy, Friedreich’s ataxia, transverse myelitis, and spina bifida).
22. Armour BS, Courtney-Long EA, Fox MH, Fredine H, Cahill A. Prevalence and Causes of Paralysis-United States, 2013. *Am J Public Health.* 2016;106(10):1855-1857.
23. Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?. *Spinal Cord.* 2006;44(9):523-529.
24. National Spinal Cord Injury Statistical Center (NSCISC): 2020 Annual Report and 2021 Facts and Figures. <https://www.nscisc.uab.edu/>
25. “Huntington’s Disease,” *Mov Disord.* 2019 Jun; 34(6): 858–865.
26. “Alzheimer’s Disease: Facts & Figures,” Brightfocus Foundation, <https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures>
27. Goodman WK, Alterman RL. Deep brain stimulation for intractable psychiatric disorders. *Annu Rev Med.* 2012;63:511-524.
28. “Stroke Facts,” Center for Disease Control and Prevention, <https://www.cdc.gov/stroke/facts.htm>
29. Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. *Int Rev Psychiatry.* 2013;25(2):130-137.

Our Company

4 Pillar Growth Strategy by 2025

Development Pipeline Over the Next Two Years

ACHIEVE GLOBAL SCALE
Expand Global Footprint to 100+ Centers
Perform Procedures w/ Remote Clinical Support
Achieve 60%+ Margins & Operational Cashflow Breakeven

4

NEW THERAPY DEVICES
Full Market Release for PRISM Neuro Laser
Integrate Tumor Segmentation Software
Activate Maestro Ablation Coverage & A.I. Predictive Modeling

3

NEURO NAVIGATION FOR DBS
Expand into the Operating Room w/ ClearPoint OR
Show Compatibility with Existing Third-Party Navigation w/ SmartFrame OR
Launch Maestro CT, Non-Rigid Fusion, Area-of-Activation and DTI Harmony Software

2

BIOLOGICS & DRUG DELIVERY
Expand Neuro Pre-Clinical CRO Services and Capacity Including GLP Capability
Expand Partnerships to Include Co-Development, Pass Through Sales, Drug Clinical Milestones & Royalty Based Agreements
Execute on Development Pipeline for Drug Infusion Monitoring/Modelling, Intracranial Cell Therapy and Spinal Routes of Administration


1

2024

2025

New Product Growth Drivers Expected in 2024


1 Biologics & Drug Delivery



ClearPoint Orchestra™ Head Fixation Frame




Spinal Infusion Anchoring Devices



Radially Branching Cell therapy Devices

2 Navigation for DBS



ClearPointer™ and SmartFrame OR™




ClearPoint 2.2 Software w/ Embedded ClearPoint Maestro®

3 Laser Therapy




PRISM 3.0 T & 1.5 T Compatible Systems
(1.5 T Compatibility not yet FDA Cleared)



Array 1.2 Parallel Trajectory Tumor Feature

A.I. Powered 'Maestro' Brain Model

- FDA Cleared, Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects
 - Auto-Segmentation for Device Targeting
 - Direct Navigation in Clinical Trials for Drug Delivery
 - Longitudinal Comparison for Pharma Trial follow-up
- **Platform Engine** for future navigation tools for Drug Delivery, DBS, BCI, Biopsy and Laser Therapy
- Expandable to CT Guidance in the Operating Room



Executive Summary



Unique platform technology

with 10+ years of commercial experience enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders



Expandable Platform

through advanced A.I. and machine learning software applications and strategic partnerships



Total potential addressable market

> \$12B for our products, pipeline and partnerships



Pipeline of new revenue streams

through the expansion into the Operating Room, Launch of our own PRISM Laser Therapy, Maestro Brain Model Deployment and addition of pre-clinical services and capacity including GLP



Large, growing number of customer and partner sites

of 75+ leading Neurosurgery and research centers worldwide, on pace to be in 100+ by 2025



A growing and passionate team

of embedded scientists and specialists





CLEARPOINT®
NEURO

